PORTFOLIO NEWS Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team January 6, 2022 Read More » Escient Pharmaceuticals Appoints Joshua Grass, MBA As CEO January 5, 2022 Read More » Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System December 23, 2021 Read More » Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer December 15, 2021 Read More » Neurona Therapeutics Announces C-Suite Leadership Team December 13, 2021 Read More » ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting December 13, 2021 Read More » Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting December 12, 2021 Read More » NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab) December 6, 2021 Read More » Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society December 3, 2021 Read More » eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology November 24, 2021 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive Leadership Team January 6, 2022 Read More »
Synthekine Announces Publication of Preclinical Data Demonstrating In Vivo Control of CD19 CAR-T Cells with its Orthogonal IL-2 System December 23, 2021 Read More »
Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer December 15, 2021 Read More »
ORIC Pharmaceuticals Presents Data Supporting the Therapeutic Potential of ORIC-533 in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting December 13, 2021 Read More »
Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting December 12, 2021 Read More »
NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab) December 6, 2021 Read More »
Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society December 3, 2021 Read More »
eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology November 24, 2021 Read More »
